clinical trialsHealth CanadavaccinesCOVID therapeuticsIn response to the COVID-19 pandemic, Canadian clinical researchers pivoted their research programs to investigate repurposing drugs, accelerating the development of experimental therapies, and developing novel disease-specific treatments. T...
Pooled data on 779 patients with B-cell malignancies who received treatment with zanubrutinib on clinical trials indicated that the most frequent AEs experienced with the agent were neutropenia, thrombocytopenia, upper respiratory tract infection, anemia, rash, musculoskeletal pain, diarrhea, cough, co...
aducanumab was nearly ab andoned after it appeared unlikely to succeed in two clinical trials. But after reanalyzing m ore data, the drug's developer Biogen saw sign s indicating the drug might work, and decided to pursue F D A approval.Still, today's decision concerns some doctor s and...
根据第二段“The drug, aducanumab, is also the first new Alzheimer's treatment approved since 2003.However, in 2019, aducanumab was nearly abandoned after it appeared unlikely to succeed in two clinical trials. But after reanalyzing more data, the drug's developer Biogen saw signs indicating ...
*In clinical trials, the primary endpoint for cervical dystonia was based on the total Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) change at Week 4. In adults with spasticity, muscle tone was assessed by the Modified Ashworth Scale (MAS) at Week 4, and in pediatric patients at...
The approval follows data from two phase 3 clinical trials. In one,miniSTONE-2, the scientists sought to discover whether Xofluza would alleviate the symptoms of flu in children already infected with the virus. They found that the drug helped alleviate symptoms in children at the same rate as...
Source: https://clinicaltrials.gov. 13.5.1. Remdesivir Remdesivir (GS-5734) is a broad-spectrum antiviral agent developed by Gilead Sciences in 2009. Originally, it was developed by the company for the treatment of hepatitis C virus diseases, but it was a failure [13,14]. Gilead Sciences ...
The trial is approved by the China Human Genetic Resources Management Office, and first patient dose is expected in early 2019.The ongoing phase Ib/IIa clinical trial of GMA102 in Australia and New Zealand has finished dosing of the 2nd cohort and the recruitment of the 3rd cohort. From the...
(BA5101) developed in-house by Boan Biotech, a subsidiary of the Group, has obtained approval from the Centre for Drug Evaluation of China’s National Medical Products Administration to begin clinical trials in the country. Boan Biotech is building a differentiated and diverse product portfolio, ...
aducanumab was nearly abandoned after it appeared unlikely to succeed in two clinical trials. But after reanalyzing more data, the drug's developer Biogen saw signs indicating the drug might work, and decided to pursue FDA approval.Still, today's decision concerns some doctors and scientists becau...